Maynard Um
-
-
-
-
-
-
-
Spyre Therapeutics, Inc. (SYRE) Tops Q3 EPS by 62c
-
-
-
-
-
-
-
Leerink Partners Reiterates Outperform Rating on Spyre (SYRE)
-
-
-
-
-
-
-
Spyre Therapeutics, Inc. (SYRE) Tops Q4 EPS by 22c
-
-
-
-
-
-
-
Spyre (SYRE) PT Raised to $65 at Guggenheim
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Spyre (SYRE)
-
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

